SCI时时刷

search
De‐risking Clinical Trials: The BIAL Phase I Trial in Foresight
De‐risking Clinical Trials: The BIAL Phase I Trial in Foresight
Disasters in early drug development are rare but, because they generally harm healthy young people, remembered for a long ...
Association of Vitamin K and Non‐Vitamin K Oral Anticoagulant Use and Cancer Incidence in Atrial Fibrillation Patients
Association of Vitamin K and Non‐Vitamin K Oral Anticoagulant Use and Cancer Incidence in Atrial Fibrillation Patients
The association between the use of vitamin K antagonists (VKAs) and cancer risk reduction remains unclear. We aimed to ass...
A systematic review and analysis of the use of polygenic scores in pharmacogenomics
A systematic review and analysis of the use of polygenic scores in pharmacogenomics
Abstract Polygenic scores (PGS) have emerged as promising tools for complex trait risk prediction. The application of thes...
Innovative Pediatric Development for Secukinumab in Psoriasis: Faster Patient Access, Reduction of Patients on Control
Innovative Pediatric Development for Secukinumab in Psoriasis: Faster Patient Access, Reduction of Patients on Control
ABSTRACT This manuscript describes the innovative pediatric development strategy of secukinumab in psoriasis. Initially, t...
Serotonin‐affecting antidepressant use in relation to platelet reactivity
Serotonin‐affecting antidepressant use in relation to platelet reactivity
Abstract Depression is an independent risk factor of cardiovascular disease morbidity. Serotonin is a key neurotransmitter...
When Can We Rely on Real‐World Evidence to Evaluate New Medical Treatments?
When Can We Rely on Real‐World Evidence to Evaluate New Medical Treatments?
Concerns regarding both the limited generalizability and the slow pace of traditional randomized trials have led to calls ...
When Can We Trust Real‐World Data To Evaluate New Medical Treatments?
When Can We Trust Real‐World Data To Evaluate New Medical Treatments?
Concerns regarding both the limited generalizability and the slow pace of traditional randomized trials have led to calls ...
When Are Treatment Blinding and Treatment Standardization Necessary in Real‐World Clinical Trials?
When Are Treatment Blinding and Treatment Standardization Necessary in Real‐World Clinical Trials?
Concerns regarding both the limited generalizability and the slow pace of traditional randomized trials have led to calls ...
Mechanistic Modelling of Primaquine Pharmacokinetics, Gametocytocidal Activity, and Mosquito Infectivity
Mechanistic Modelling of Primaquine Pharmacokinetics, Gametocytocidal Activity, and Mosquito Infectivity
Abstract Clinical studies have shown that adding a single 0.25mg base/kg dose of primaquine to standard antimalarial regim...
Clinical Pharmacology Perspectives for Adoptive Cell Therapies in Oncology
Clinical Pharmacology Perspectives for Adoptive Cell Therapies in Oncology
Abstract Adoptive cell therapies (ACTs) have shown transformative efficacy in oncology with five FDA approvals for CAR T-c...
Can In Vitro–In Vivo Extrapolation Be Successful? Recognizing the Incorrect Clearance Assumptions
Can In Vitro–In Vivo Extrapolation Be Successful? Recognizing the Incorrect Clearance Assumptions
For a number of years, our laboratory has been investigating the underlying reasons for the published poor in vitro–...
Effect of CYP3A5 and CYP3A4 Genetic Variants on Fentanyl Pharmacokinetics in a Pediatric Population
Effect of CYP3A5 and CYP3A4 Genetic Variants on Fentanyl Pharmacokinetics in a Pediatric Population
Abstract Fentanyl is an anesthetic/analgesic commonly used in surgical and recovery settings. CYP3A4 and CYP3A5 encode enz...
Features of inflammatory heart reactions following mRNA COVID‐19 vaccination at a global level
Features of inflammatory heart reactions following mRNA COVID‐19 vaccination at a global level
ABSTRACT Myocarditis and pericarditis may constitute adverse reactions of mRNA COVID-19 vaccines. This study aimed to docu...
Clinical Pharmacology in Drug Development for Rare Diseases in Neurology: Contributions and Opportunities
Clinical Pharmacology in Drug Development for Rare Diseases in Neurology: Contributions and Opportunities
Abstract Several challenges are associated with rare disease drug development in neurology. In this article, we summarize ...
Anticoagulant treatment regimens in patients with Covid‐19: a meta‐analysis
Anticoagulant treatment regimens in patients with Covid‐19: a meta‐analysis
Abstract Coronavirus disease 2019 (Covid-19) is associated with a hypercoagulable state. It has been hypothesized that hig...
Analysis of FDA Oncology Approvals on the Characterization of Hepatic Impairment Effect and Dosing Recommendations
Analysis of FDA Oncology Approvals on the Characterization of Hepatic Impairment Effect and Dosing Recommendations
Abstract Cancer patients with advanced hepatic impairment (HI) (ie, moderate and severe impairment) are often excluded fro...
The Structured Process to Identify Fit‐For‐Purpose Data: A Data Feasibility Assessment Framework
The Structured Process to Identify Fit‐For‐Purpose Data: A Data Feasibility Assessment Framework
To complement real-world evidence (RWE) guidelines, the 2019 Structured Preapproval and Postapproval Comparative study des...